BAY1067197
As of the edition of 20 October 2026, BAY1067197 is a small molecule: stopped in 2018; acts on ADORA1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Small molecule
- Registered trials
- 5, 2 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADORA1 | Adenosine receptor A1 | P30542 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 2 |
| Phase 2 | 3 | 3 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bayer | Lead sponsor of trials | 2013 to now |